[Evaluation of Chai Shao Liu Jun Tang for the treatment of chronic hepatitis B].
OBJECTIVE
To evaluate the effect of Chai Shao Liu Jun Tang in combination with Lamivudine for the treatment chronic hepatitis B (CHB) patients.


METHODS
405 CHB patients in Guangdong Provincial Hospital were randomly divided into 2 groups, 220 in the treated group, and 185 in the control group. The control group was treated with Lamivudine for 18 months. The treated group was treated with Lamivudine in combination with Chai Shao Liu Jun Tang for 18months. At the 3rd, 6th, 9th, 12th and 18th month during the treatment, the clinical symptoms, ALT normalization rate, HBeAg seroconversion rate, the proportion of patients with undetectable serum HBV DNA, and YMDD mutation rate were observed.


RESULTS
ALT normalization rates at the 3rd, 6th, 12th, 18th month of the treatment group (69.5%, 85.9%, 90.5%, 82.7%) were higher than those in the control group (50.3%, 65.4%, 78.4%, 69.7%; P < 0.01). HBeAg seroconversion rate, rate of HBV DNA undetectable, and YMDD mutation rate at he 12th and18th month are 77.7%, 57.7%, 25.5%, 6.8%; 86.8%, 74.1%, 33.2%, 8.6% in the treatment group, and 54.6%, 36.8%, 13.0%, 14.6%; 69.2%, 37.3%, 19.5%, 20.5% in the control group (P < 0.01, or P < 0.05).


CONCLUSIONS
Compared to lamivudine alone, Cai Shao Liu Ju Tang in combination with lamivudine is more effective and induces less YMDD mutation rate in CHB patients.
Chi
Xiao-ling
XL
Department of Liver Diseases, Guangdong Provincial Hospital of TCM, Guangzhou, China. chixiaolingqh@163.com
Wu
Li-ming
LM
Jiang
Jun-min
JM
Chen
Pei-qiong
PQ
Tian
Guang-jun
GJ
Xiao
Huan-ming
HM
Cai
Gao-shu
GS
Chen
Ying
Y
Qian
Ying
Y
D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D004279:DNA, Viral / Q000097:blood / Q000235:genetics; D004338:Drug Combinations; D024882:Drug Resistance, Viral; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005814:Genes, Viral; D006513:Hepatitis B e Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000187:drug effects / Q000235:genetics*; D019694:Hepatitis B, Chronic / Q000097:blood / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage / Q000627:therapeutic use*; D008111:Liver Function Tests; D008297:Male; D008516:Medicine, Chinese Traditional; D009154:Mutation; D008517:Phytotherapy; D016896:Treatment Outcome; D014779:Virus Replication / Q000187:drug effects*
D004279:DNA, Viral; D004338:Drug Combinations; D004365:Drugs, Chinese Herbal; D006513:Hepatitis B e Antigens; D019259:Lamivudine; D000410:Alanine Transaminase